This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Cantero Therapeutics, Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: The Innovations of Marc-Andre Beaulieu
Introduction
Marc-Andre Beaulieu is a notable inventor based in L'Assomption, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that can aid in treating specific medical conditions. His work focuses on innovative solutions that address critical health issues.
Latest Patents
Marc-Andre Beaulieu holds a patent for triazole glycolate oxidase inhibitors. This invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. The patent also describes pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH), and kidney stones.
Career Highlights
Beaulieu is currently associated with Cantero Therapeutics, Inc., where he continues to advance his research and development efforts. His work is pivotal in creating effective treatments that can improve patient outcomes in the field of urology.
Collaborations
Some of his notable coworkers include Hans Maag and Miguel Xavier Fernandes. Their collaborative efforts contribute to the innovative environment at Cantero Therapeutics, Inc.
Conclusion
Marc-Andre Beaulieu's contributions to pharmaceutical innovations highlight the importance of research in developing effective treatments for complex medical conditions. His work exemplifies the impact that dedicated inventors can have on healthcare advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile